TY - JOUR
T1 - Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma
AU - Mittra, Erik
AU - El-Maghraby, Tarek
AU - Rodriguez, Cesar A.
AU - Quon, Andrew
AU - Ross McDougall, I.
AU - Gambhir, Sanjiv S.
AU - Iagaru, Andrei
N1 - Funding Information:
Acknowledgements This research was supported in part by NCI ICMIC CA114747 (SSG) and the clinical studies were supported in part by the Doris Duke Foundation and Canary Foundation (SSG).
PY - 2009/12
Y1 - 2009/12
N2 - Purpose: Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon. Methods: This is a retrospective study of 30 women with cervical carcinoma who had a surveillance PET/CT after initial therapy. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated using a 2×2 contingency table with pathology results (76%) or clinical follow-up (24%) as the gold standard. The Wilson score method was used to perform 95% confidence interval estimations. Results: The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for the detection of local recurrence at the primary site were 93, 93, 93, 86, and 96%, respectively. The same values for the detection of distant metastases were 96, 95, 95, 96, and 95%, respectively. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings. In comparison, 44% of scans performed in asymptomatic patients showed true-positive findings. But, all patients subsequently had a change in their management based on the PET/CT findings such that the effect was notable. The maximum standardized uptake value ranged from 5 to 28 (average: 13±7) in the primary site and 3 to 23 (average: 8±4) in metastases which were significantly different (p=0.04). Conclusion: This study demonstrates favorable efficacy of 18F-FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for localization of distant metastases.
AB - Purpose: Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon. Methods: This is a retrospective study of 30 women with cervical carcinoma who had a surveillance PET/CT after initial therapy. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated using a 2×2 contingency table with pathology results (76%) or clinical follow-up (24%) as the gold standard. The Wilson score method was used to perform 95% confidence interval estimations. Results: The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for the detection of local recurrence at the primary site were 93, 93, 93, 86, and 96%, respectively. The same values for the detection of distant metastases were 96, 95, 95, 96, and 95%, respectively. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings. In comparison, 44% of scans performed in asymptomatic patients showed true-positive findings. But, all patients subsequently had a change in their management based on the PET/CT findings such that the effect was notable. The maximum standardized uptake value ranged from 5 to 28 (average: 13±7) in the primary site and 3 to 23 (average: 8±4) in metastases which were significantly different (p=0.04). Conclusion: This study demonstrates favorable efficacy of 18F-FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for localization of distant metastases.
KW - Cervical cancer
KW - Efficacy
KW - F-FDG
KW - PET/CT
KW - Restaging
UR - http://www.scopus.com/inward/record.url?scp=71849091302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71849091302&partnerID=8YFLogxK
U2 - 10.1007/s00259-009-1206-x
DO - 10.1007/s00259-009-1206-x
M3 - Article
C2 - 19585114
AN - SCOPUS:71849091302
SN - 1619-7070
VL - 36
SP - 1952
EP - 1959
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 12
ER -